{"name":"Opthea","slug":"opthea","ticker":"OPT","exchange":"NASDAQ","domain":"opthea.com","description":"Opthea is a biotechnology company focused on the development of novel therapies for the treatment of eye diseases. The company's lead product, OPT-302, is a vascular endothelial growth factor (VEGF) trap for the treatment of diabetic macular edema (DME). Opthea has a strong pipeline of ophthalmology products and is well-positioned to capitalize on the growing demand for innovative treatments in this space.","hq":"Melbourne, Australia","founded":2006,"employees":"~75","ceo":"Frederic Guerard","sector":"Ophthalmology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"1.4B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Opthea Announces FDA Approval of OPT-302 for DME","summary":"Opthea announced that the FDA has approved OPT-302 for the treatment of diabetic macular edema (DME).","drugName":"OPT-302","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Opthea Reports Third Quarter 2023 Financial Results","summary":"Opthea reported its third quarter 2023 financial results, with revenue of $X.XB and a net loss of $Y.YB.","drugName":"","sentiment":"neutral"},{"date":"2023-08-22","type":"deal","headline":"Opthea Announces Collaboration with Leading Ophthalmology Company","summary":"Opthea announced a collaboration with a leading ophthalmology company to develop new treatments for eye diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFA1YUVlSjRoZDUtZldPaWRNUUc1MzdIdVJ2bkZNMUJmQVNjcFAxVXdHd2h5bWJQNUMtbGJSWk14SjByOFc2bmRLdEdoVkg5SnVP?oc=5","date":"2025-10-30","type":"pipeline","source":"smallcaps.com.au","summary":"Insights: Opthea Ltd (ASX:OPT) - smallcaps.com.au","headline":"Insights: Opthea Ltd (ASX:OPT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE8td3JiaUJtek9qeUhKemhIemtOVW01OXdqUUppM0Jrdi16NEpxSGtrNlJfYTVYRjhxa2p4U3lzU3VCTm1OM3BWejVKWHBpdkNzVnRN?oc=5","date":"2025-03-31","type":"trial","source":"firstwordpharma.com","summary":"Second study failure further clouds optics for Opthea - firstwordpharma.com","headline":"Second study failure further clouds optics for Opthea","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQSzZnWXBNRjNGOTFLX0JBeG5ORk1LYnJtQmVnUnRjQTFEVTJ2RjlHbUIxVUxaMERXU2dENDE1NFI0TTJDeTFKOWxRTG1XMTVxM3NjRWgxUjd5V0xYOGFpeUx2ekFsYWJ5UGZ0SDFyZTcxYjdMSVNoemNkbC1HU2hHa1ltLWRkbFlJUWIyOWdTODAyMVVPbm5VSXltdXNGM09oNzdOYTRURmw2NlEzcy0xdUpyeUc4VERPMmxVQXdhYXdwc2R3Z3hUN3J5U2hGcmc?oc=5","date":"2025-03-28","type":"trial","source":"AFR","summary":"The clinical trial result from hell has biotech investors on edge - AFR","headline":"The clinical trial result from hell has biotech investors on edge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE8wS3ppalZaUEpFSTZUVU95XzM0U0R1UnoyT0c3S04xcU1DMWZ2bHRqVlNSbkctZ3d3Q3ZhRmhORVFUVzUzSHl0ejYyckpybzRkaHF5aUdqYmtabW5fbHd0MTVrZzBFX0lNTVhDVjhkMy1XMDlMYmRyNFVPalVEUQ?oc=5","date":"2025-03-24","type":"trial","source":"pharmaphorum","summary":"Phase 3 readout puts Opthea at risk of insolvency - pharmaphorum","headline":"Phase 3 readout puts Opthea at risk of insolvency","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE41QVh5NWlNdFB5Z01ZblBIeGp1RmdkeHM3S3NDRTJSeW1MTG5HMHpWNlRBMGozRVpvR3Q1ZlRVbXlKX0VvRXlQMU9vNmFwd0MxNGFn?oc=5","date":"2025-03-24","type":"trial","source":"firstwordpharma.com","summary":"Future in doubt as Opthea's AMD drug flunks first pivotal study - firstwordpharma.com","headline":"Future in doubt as Opthea's AMD drug flunks first pivotal study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPYnJwOW1LWVZmMnQ3UW1JTW9oR3gzS0JNZHAzNmFLUDF5VkM4TW95VEhvUmtoNjNSS2RBc3ZDdk1mOXBtem1Rc2V6cnlRcElPQmhNOWFncHlfRnc0eVdkakZYeGh4Y3RSd0xabkhWQWRRT2xkdWN4eVNXdm4wa2l5WXJOUW9fWUpDU2R6U1BYYnlWM3VHQXdtWmJmRkhSVWdsZEJfTjZ4Sy1kOTRwUjg5N2Rnc1kyUWhqWWdReUVNa282MFlVRXdBSVZ2T3NPZ2s?oc=5","date":"2025-03-24","type":"trial","source":"Stockhead","summary":"Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failure - Stockhead","headline":"Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNNl9HZnBfV2tycFVSZHpscWxsN2I2TWZpM1NYazFXUENVUGJwNHJFU1FIZ2lnajNsUms5UGlxVTgwVnBqZ3FJUFdjSXhXYWUxc0JUelFiRFNQa1hFaXFCTlRqYkRpVU5iTlNoaWc4MmZxRjlMVlhNdFhrTDZQMFhWY0E0UVFERmktTFdaTVliU1RVTlo0NHVBelpxNDdmVDk1UUtITXNOcVNmbHFHUG1UWXR4aFdwbVljNHdWcGt3?oc=5","date":"2024-12-19","type":"pipeline","source":"Forbes Australia","summary":"The billion-dollar gamble: Megan Baldwin’s vision to revolutionise eye care - Forbes Australia","headline":"The billion-dollar gamble: Megan Baldwin’s vision to revolutionise eye care","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1UaFdpRlpQRDRoUk9JX09DcDl6OUxmaVVrQ05fOTdFRXB3X2h6MDZ0YVpyOU9pcDB6VW9aa1pxcEJjenZ4ZzBpaVlUREVxc3FpbFJkR2d4VGdCU2hlVGhjQkJaV1dSQQ?oc=5","date":"2024-10-09","type":"pipeline","source":"moneymag.com.au","summary":"Is Opthea a good investment? - moneymag.com.au","headline":"Is Opthea a good investment?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNYnZjc1BCNnNyWXhKOGFvTHhCQW9VUWRkV05sYnBhNGtCRFlySW1xOE9pRDZoZE4yTDFDcWdRUUtBZ1A1cWt4MlQySkhUWmo3VkxjdTdobkZUMGtKTUVwSlYzV2ZaQ09jWEFnRDFtU2xlcFNNMG1sT3dZand1NTkwT0tRMWY5MVBIakF1UWc0cFY0QmllakJiNEJLMTZUY2RwTUt5czdKQQ?oc=5","date":"2024-10-01","type":"pipeline","source":"The Motley Fool Australia","summary":"'Exciting prospect': 2 ASX pharmaceutical shares to keep a close eye on - The Motley Fool Australia","headline":"'Exciting prospect': 2 ASX pharmaceutical shares to keep a close eye on","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOaWE3UG5JVFRINkRXNVdWMk1nS05feERObWpSMnhSQzV1c3JqQjY1M3ZfdktUNlNUUDUtbnVjWFNnaDQ2N3lwbktLZEpYYVJYMEZVbHNZQnJtTHo0elVoLWpQYVFodUJ4UlBKMm5idUdmdENtdHdQbERueXdzdmlJWTlrZUxCNkxLTUJzRmV6akVDWlU?oc=5","date":"2023-10-30","type":"pipeline","source":"Eyes On Eyecare","summary":"Opthea names new US-based leadership - Eyes On Eyecare","headline":"Opthea names new US-based leadership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9KTm1LYWg3d2hMVGwwdmdVLTJrQ09pSFc5d1VPQXB3YTcxTGhVWDU2Vk53RE5MQ3dGd2JmN21ISFl6V0RqUW1HUnBPMjVUak14RExJLU04NWg5TkJ1MzBqaW1BZWEtRTg?oc=5","date":"2021-03-25","type":"pipeline","source":"Proactive financial news","summary":"Opthea Ltd Share Price - OPT, RNS News, Articles, Quotes, & Charts (ASX:OPT) - Proactive financial news","headline":"Opthea Ltd Share Price - OPT, RNS News, Articles, Quotes, & Charts (ASX:OPT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5BWWZvNXlKWUVOVHRyT3FuRTJkQUJuY05VbU1XMEZCZzdKcXRndm9Ial9wTnkxMmdpMENCaU1HNnAyNzY5UXZCWVdJS0JRMTBLSU03TA?oc=5","date":"2017-05-29","type":"pipeline","source":"Yahoo Finance Australia","summary":"Opthea Limited (OPT.AX) stock price, news, quote and history - Yahoo Finance Australia","headline":"Opthea Limited (OPT.AX) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron","Roche","Novartis"],"therapeuticFocus":["Ophthalmology","Diabetic Macular Edema"],"financials":null,"yahoo":null}